DxN Veris
Device
Beckman Coulter, Inc.
Total Payments
$1.5M
Transactions
37
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.5M | 37 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 37 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Molecular CTNG testing | Beckman Coulter, Inc. | $1.0M | 0 |
| TV CTNG Specimen Testing | Beckman Coulter, Inc. | $416,119 | 0 |
| Molecular assay performance evaluation | Beckman Coulter, Inc. | $17,302 | 0 |
| Clinical Evlaution of the VERIS CMV | Beckman Coulter, Inc. | $6,228 | 0 |
Top Doctors Receiving Payments for DxN Veris
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $1.5M | 37 |
Ad
Manufacturing Companies
- Beckman Coulter, Inc. $1.5M
Product Information
- Type Device
- Total Payments $1.5M
- Total Doctors 0
- Transactions 37
About DxN Veris
DxN Veris is a device associated with $1.5M in payments to 0 healthcare providers, recorded across 37 transactions in the CMS Open Payments database. The primary manufacturer is Beckman Coulter, Inc..
Payment data is available from 2017 to 2017. In 2017, $1.5M was paid across 37 transactions to 0 doctors.
The most common payment nature for DxN Veris is "Unspecified" ($1.5M, 100.0% of total).
DxN Veris is associated with 4 research studies, including "Molecular CTNG testing" ($1.0M).